High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane

We determined whether progression‐free survival (PFS) in metastatic breast cancer (MBC) patients receiving everolimus plus exemestane (EVE/EXE) varies depending on circulating tumour DNA (ctDNA) characteristics. Baseline plasma cell‐free DNA (cfDNA) from 164 postmenopausal women with ER‐positive, HE...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruger, Dinja T., Jansen, Maurice P.H.M., Konings, Inge R.H.M., Dercksen, Wouter M., Jager, Agnes, Oulad Hadj, Jamal, Sleijfer, Stefan, Martens, John W.M., Boven, Epie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053245/
https://www.ncbi.nlm.nih.gov/pubmed/31841262
http://dx.doi.org/10.1002/1878-0261.12617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053245/
https://www.ncbi.nlm.nih.gov/pubmed/31841262
http://dx.doi.org/10.1002/1878-0261.12617

Ejemplares similares